This mechanistic framework extends to surface oncoproteins like Delta-like ligand 3 (DLL3), which exhibits tumor-selective overexpression in 70–80% of SCLC cases versus negligible normal tissue expression—establishing its dual role as a biomarker and therapeutic target with intrinsic immunogenic potential (22–25). This evidence concerns the gene DLL3 and small cell lung carcinoma.